Heptanoic Acid → 4-[5-(4-Heptanoyl-piperazin-1-ylmethyl)-imidazol-1-ylmethyl]-benzonitrile
반응식
[C:1]([C:3]1[CH:21]=[CH:20][C:6]([CH2:7][N:8]2[CH2:13][CH2:12][NH:11][CH2:10][CH:9]2[CH2:14]C2NC=NC=2)=[CH:5][CH:4]=1)#[N:2].[C:22]([OH:30])(=O)[CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][CH3:28].O[N:32]1C2C=CC=CC=2N=N1.[CH2:41]([N:43]([CH2:46]C)CC)[CH3:42].Cl.CN(C)CCCN=C=NCC>CN(C)C=O.C(OCC)(=O)C>[C:22]([N:43]1[CH2:46][CH2:12][N:11]([CH2:10][C:9]2[N:8]([CH2:7][C:6]3[CH:5]=[CH:4][C:3]([C:1]#[N:2])=[CH:21][CH:20]=3)[CH:13]=[N:32][CH:14]=2)[CH2:42][CH2:41]1)(=[O:30])[CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][CH3:28]참가 물질
반응물 5
생성물 1
시약·촉매·용매 2
실험 절차
To a solution of 1-(4′-Cyanobenzyl)imidazol-5-ylmethyl piperazine, prepared as described in Example 1 (65 mg, 0.18 mmol), in 0.5 mL of dimethylformamide at room temperature was added heptanoic acid (0.028 mL, 0.2 mmol), 1-hydroxybenzotriazole (30 mg, 0.22 mmol), triethylamine (0.10 mL, 0.72 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (42 mg, 0.22 mmol). After sti!ting overnight, the solution was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and brine, dried with sodium sulfate, filtered, and concentrated in vacuo. Purification by preparative HPLC was followed by conversion to the bis-hydrochloride salt by exposure of a dichloromethane solution of the product to excess ethereal HCl. Concentration in vacuo provided the titled product as a white powder (23 mg). MS: found: 394 (M+H+)
후처리
- washwashed with saturated sodium bicarbonate solution and brine
- dry with materialdried with sodium sulfate
- filtrationfiltered
- concentrationconcentrated in vacuo
- customPurification by preparative HPLC
- concentrationConcentration in vacuo
출처 및 근거
- ORD 기록
- ord-5aa75ee985764e388cc94752066ba9ca
- 출처 데이터셋
- uspto-grants-2002_03
- 특허 번호
- US06355643B1
반응 노트
불러오는 중…